Henrique Vara L.
- Country
- Portugal
- Department
- N/A
Research Overview
Data & Insights
Has run more than one trial at 0 of 60 partner sites.
Specializations
Cardiovascular and Metabolic Disorders
Investigator Henrique Vara Luiz focuses on atherosclerotic cardiovascular disease, hypertension, acute ischemic stroke, and metabolic risk factors associated with type 2 diabetes.
- Primary prevention of ischemic stroke
- LDL‑C lowering strategies
- Blood pressure modulation in high‑risk populations
Research aims to reduce major adverse cardiovascular events and improve long‑term outcomes in patients with established disease.
Oncology and Hematologic Malignancies
His portfolio includes studies on advanced/metastatic non‑small cell lung cancer, colorectal cancer, breast neoplasms, and polycythemia vera.
- Targeted therapy for HER2‑positive colorectal cancer
- Immune checkpoint inhibition in metastatic melanoma
- JAK2 inhibition in polycythemia vera
Efforts concentrate on extending survival and evaluating novel combination regimens across solid and hematologic tumors.
Pulmonary and Respiratory Diseases
He is engaged in clinical work for pulmonary arterial hypertension, chronic obstructive pulmonary disease, and interstitial lung disease secondary to systemic sclerosis.
- Triple‑therapy versus dual‑therapy in PAH
- Antifibrotic agents in COPD exacerbation reduction
- Hemodynamic endpoints in SSc‑associated ILD
These studies target improved functional capacity and reduced disease progression in high‑risk respiratory cohorts.
Neurological and Autoimmune Disorders
His investigations cover multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, and systemic lupus erythematosus.
- Long‑term safety of B‑cell depletion in MS
- Biomarker‑guided therapy withdrawal in CIDP
- Novel agents for early SLE disease control
Objectives include sustaining neurological function and minimizing immunosuppressive exposure.
Renal and Hepatic Fibrosis Conditions
He contributes to trials addressing non‑alcoholic steatohepatitis, chronic kidney disease, and proteinuric kidney diseases.
- Semaglutide impact on NASH histology
- Finerenone for slowing CKD progression
- Albumin‑creatinine ratio reduction in autosomal dominant polycystic kidney disease
Research seeks to halt fibrotic pathways and preserve organ function in metabolic and renal disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.